Toxicity appears higher than that with single-agent anti-VEGF therapy, with two-thirds of the patients developing hypertension and 79% incidence of grade 1–3 hand–foot syndrome (Azad et al, 2008). The gene discussed is VEGFA; the disease is hypertensive disorder.